U.S.: Medicaments Containing Insulin Market 2023

Medicaments Containing Insulin Market Size in the U.S.

In 2022, the U.S. medicaments containing insulin market increased by X% to $X, rising for the second consecutive year after three years of decline. In general, consumption, however, showed a perceptible curtailment. Over the period under review, the market reached the maximum level at $X in 2012; however, from 2013 to 2022, consumption remained at a lower figure.

Medicaments Containing Insulin Production in the U.S.

In value terms, medicaments containing insulin production fell modestly to $X in 2022. Overall, production, however, recorded a abrupt descent. The pace of growth appeared the most rapid in 2021 when the production volume increased by X%. Medicaments containing insulin production peaked at $X in 2012; however, from 2013 to 2022, production failed to regain momentum.

Medicaments Containing Insulin Exports

Exports from the U.S.

In 2022, shipments abroad of medicaments containing insulin but not antibiotics decreased by X% to X tons, falling for the second year in a row after three years of growth. Overall, exports faced a deep contraction. The pace of growth was the most pronounced in 2019 with an increase of X%. Over the period under review, the exports hit record highs at X tons in 2020; however, from 2021 to 2022, the exports remained at a lower figure.

In value terms, medicaments containing insulin exports declined sharply to $X in 2022. Over the period under review, exports continue to indicate a dramatic contraction. The pace of growth appeared the most rapid in 2018 when exports increased by X%. The exports peaked at $X in 2019; however, from 2020 to 2022, the exports stood at a somewhat lower figure.

Exports by Country

Denmark (X tons) was the main destination for medicaments containing insulin exports from the United States, with a X% share of total exports. It was followed by China (X kg), with a X% share of total exports.

From 2012 to 2022, the average annual growth rate of volume to Denmark was relatively modest.

In value terms, Denmark ($X) remains the key foreign market for medicaments containing insulin but not antibiotics exports from the United States, comprising X% of total exports. The second position in the ranking was held by China ($X), with a X% share of total exports.

From 2012 to 2022, the average annual rate of growth in terms of value to Denmark amounted to X%.

Export Prices by Country

In 2022, the average medicaments containing insulin export price amounted to $X per ton, increasing by X% against the previous year. Over the period under review, the export price, however, recorded a deep slump. The export price peaked at $X per ton in 2012; however, from 2013 to 2022, the export prices failed to regain momentum.

Prices varied noticeably by country of destination: amid the top suppliers, the country with the highest price was China ($X,133 per ton), while the average price for exports to Denmark totaled $X per ton.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to China (X%), while the prices for the other major destinations experienced a decline.

Medicaments Containing Insulin Imports

Imports into the U.S.

In 2022, after two years of growth, there was significant decline in overseas purchases of medicaments containing insulin but not antibiotics, when their volume decreased by X% to X kg. In general, imports saw a precipitous decline. The most prominent rate of growth was recorded in 2015 when imports increased by X% against the previous year. Imports peaked at X tons in 2012; however, from 2013 to 2022, imports remained at a lower figure.

In value terms, medicaments containing insulin imports contracted notably to $X in 2022. Overall, imports faced a precipitous contraction. The most prominent rate of growth was recorded in 2015 with an increase of X%. Over the period under review, imports attained the maximum at $X in 2012; however, from 2013 to 2022, imports stood at a somewhat lower figure.

Imports by Country

In 2022, the UK (X kg) constituted the largest supplier of medicaments containing insulin to the United States, with a X% share of total imports. Moreover, medicaments containing insulin imports from the UK exceeded the figures recorded by the second-largest supplier, Denmark (X kg), twofold.

From 2012 to 2022, the average annual growth rate of volume from the UK amounted to X%.

In value terms, the UK ($X) and Denmark ($X) appeared to be the largest medicaments containing insulin suppliers to the United States.

In terms of the main suppliers, the UK, with a CAGR of X%, recorded the highest rates of growth with regard to the value of imports, over the period under review.

Import Prices by Country

The average medicaments containing insulin import price stood at $X per ton in 2022, shrinking by X% against the previous year. In general, the import price showed a deep downturn. The pace of growth was the most pronounced in 2017 an increase of X% against the previous year. Over the period under review, average import prices hit record highs at $X per ton in 2013; however, from 2014 to 2022, import prices stood at a somewhat lower figure.

Average prices varied noticeably amongst the major supplying countries. In 2022, amid the top importers, the country with the highest price was Denmark ($X per ton), while the price for the UK amounted to $X per ton.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by the UK (X%).

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :